Accessibility Menu

Some price data may be temporarily unavailable.

KEY DATA POINTS

Current Price
$0.00
Daily Change
(-) $0.00
Day's Range
$0.00 - $0.00
Previous Close
$0.00
Open
$0.00
Beta
0
Volume
-
Average Volume
-
Market Cap
-
Market Cap / Employee
-
52wk Range
$0.00 - $0.00
Revenue
-
Gross Margin
-
Dividend Yield
-
EPS
$0.00
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Neoleukin Therapeutics Company Info

Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA.

News & Analysis

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.